Search
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalAnifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … erythematosus, but so far only anifrolumab has been approved.
Categories: Type I Interferon Receptor AntagonistProducts: Saphnelo 300 mg/2 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADETClofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnClofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. … It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: CLOFZIMIN® 100 MGNicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnDespite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, … Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option.
Mixtures: Nonivamid + Nicoboxil Zentiva 4 mg/g + 25 mg/g SalbeCategories: Heterocyclic Compounds, 1-RingEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
go.drugbank.com/conditions/DBCOND0111347Drugs: VepdegestrantSynonyms: Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigationalDesvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. … Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD.
Synonyms: O-desmethylvenlafaxineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsLutein
go.drugbank.com/drugs/DB00137ApprovedNutraceuticalLutein is synthesized only by plants and like other xanthophylls is found in high quantities in green leafy vegetables such as spinach, kale and yellow carrots. … In green plants, xanthophylls act to modulate light energy and serve as non-photochemical quenching agents to deal with triplet chlorophyll (an excited form of chlorophyll), which is overproduced at very
Mixtures: Furryden Dental Easy Green, RE FAC-xEarly Stage Estrogen Receptor (ER) Positive Breast Cancer
go.drugbank.com/conditions/DBCOND0068305Drugs: TamoxifenSynonyms: Early Stage Estrogen Receptor (ER) Positive Breast CancerTalc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalIn fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent. … Talc is a mineral composed primarily of magnesium, silicon and oxygen.
Synonyms: E-553(III)Categories: Compounds used in a research, industrial, or household settingVorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalA recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier … Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease
Products: ZOLINZA®VORINOSTAT 100 MG CAPSULASDamoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigationalIn recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. … [L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609]